Steroid sparing in kidney transplantation: Changing paradigms, improving outcomes, and remaining questions
被引:61
作者:
Augustine, Joshua J.
论文数: 0引用数: 0
h-index: 0
机构:Univ Hosp Cleveland, Div Nephrol & Hypertens, Cleveland, OH 44106 USA
Augustine, Joshua J.
Hricik, Donald E.
论文数: 0引用数: 0
h-index: 0
机构:Univ Hosp Cleveland, Div Nephrol & Hypertens, Cleveland, OH 44106 USA
Hricik, Donald E.
机构:
[1] Univ Hosp Cleveland, Div Nephrol & Hypertens, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA
来源:
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
|
2006年
/
1卷
/
05期
关键词:
D O I:
10.2215/CJN.01800506
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
The widely known adverse effects of long-term therapy with corticosteroids have motivated increasing interest in steroid-free immunosuppression for kidney transplant recipients. Results from recent trials that used newer immunosuppressants to facilitate elimination of steroids suggest better short-term results than were achieved in an earlier era. However, the best results have been reported in uncontrolled trials of low-risk patients or in randomized trials with relatively short periods of follow-up. Increasingly, the therapeutic paradigm has shifted from late withdrawal of steroids to very early withdrawal after transplantation or even complete avoidance. Induction antibody therapy has been used routinely in the most successful trials that involved early steroid withdrawal or avoidance. Although the outcomes of kidney transplant recipients who are treated with steroid-free immunosuppression are improving steadily, there still is room for concern in recommending this strategy as a standard of practice.